These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 16971132)

  • 1. Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs.
    Al-Rashood ST; Aboldahab IA; Nagi MN; Abouzeid LA; Abdel-Aziz AA; Abdel-Hamide SG; Youssef KM; Al-Obaid AM; El-Subbagh HI
    Bioorg Med Chem; 2006 Dec; 14(24):8608-21. PubMed ID: 16971132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones.
    Al-Omary FA; Abou-Zeid LA; Nagi MN; Habib el-SE; Abdel-Aziz AA; El-Azab AS; Abdel-Hamide SG; Al-Omar MA; Al-Obaid AM; El-Subbagh HI
    Bioorg Med Chem; 2010 Apr; 18(8):2849-63. PubMed ID: 20350811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifolate and antiproliferative activity of 6,8,10-triazaspiro[4.5]deca-6,8-dienes and 1,3,5-triazaspiro[5.5]undeca-1,3-dienes.
    Ma X; Chui WK
    Bioorg Med Chem; 2010 Jan; 18(2):737-43. PubMed ID: 20036565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
    Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
    J Med Chem; 1996 Mar; 39(7):1438-46. PubMed ID: 8691474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
    Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
    Gangjee A; Lin X; Kisliuk RL; McGuire JJ
    J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones.
    Al-Omary FA; Hassan GS; El-Messery SM; Nagi MN; Habib el-SE; El-Subbagh HI
    Eur J Med Chem; 2013 May; 63():33-45. PubMed ID: 23454532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipophilic conjugates of methotrexate with short-chain alkylamino acids as DHFR inhibitors. Synthesis, biological evaluation, and molecular modeling.
    Pignatello R; Guccione S; Forte S; Di Giacomo C; Sorrenti V; Vicari L; Uccello Barretta G; Balzano F; Puglisi G
    Bioorg Med Chem; 2004 Jun; 12(11):2951-64. PubMed ID: 15142554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
    Gangjee A; Adair O; Queener SF
    J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl- L-ornithine (PT523).
    Rosowsky A; Wright JE; Vaidya CM; Bader H; Forsch RA; Mota CE; Pardo J; Chen CS; Chen YN
    J Med Chem; 1998 Dec; 41(26):5310-9. PubMed ID: 9857098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors.
    Al-Rashood ST; Hassan GS; El-Messery SM; Nagi MN; Habib EE; Al-Omary FAM; El-Subbagh HI
    Bioorg Med Chem Lett; 2014 Sep; 24(18):4557-4567. PubMed ID: 25139568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.
    Santos MA; Enyedy EA; Nuti E; Rossello A; Krupenko NI; Krupenko SA
    Bioorg Med Chem; 2007 Feb; 15(3):1266-74. PubMed ID: 17127067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
    Kuyper LF; Baccanari DP; Jones ML; Hunter RN; Tansik RL; Joyner SS; Boytos CM; Rudolph SK; Knick V; Wilson HR; Caddell JM; Friedman HS; Comley JC; Stables JN
    J Med Chem; 1996 Feb; 39(4):892-903. PubMed ID: 8632413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
    Robson C; Meek MA; Grunwaldt JD; Lambert PA; Queener SF; Schmidt D; Griffin RJ
    J Med Chem; 1997 Sep; 40(19):3040-8. PubMed ID: 9301666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclassical antifolates, part 4. 5-(2-aminothiazol-4-yl)-4-phenyl-4H-1,2,4-triazole-3-thiols as a new class of DHFR inhibitors: synthesis, biological evaluation and molecular modeling study.
    Hassan GS; El-Messery SM; Al-Omary FA; Al-Rashood ST; Shabayek MI; Abulfadl YS; Habib el-SE; El-Hallouty SM; Fayad W; Mohamed KM; El-Menshawi BS; El-Subbagh HI
    Eur J Med Chem; 2013 Aug; 66():135-45. PubMed ID: 23792351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism inspired development of rationally designed dihydrofolate reductase inhibitors as anticancer agents.
    Singh P; Kaur M; Sachdeva S
    J Med Chem; 2012 Jul; 55(14):6381-90. PubMed ID: 22734697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
    Gangjee A; Yu J; McGuire JJ; Cody V; Galitsky N; Kisliuk RL; Queener SF
    J Med Chem; 2000 Oct; 43(21):3837-51. PubMed ID: 11052789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine (PBD) conjugates: Design, synthesis and biological evaluation as potential anticancer agents.
    Kamal A; Vijaya Bharathi E; Janaki Ramaiah M; Dastagiri D; Surendranadha Reddy J; Viswanath A; Sultana F; Pushpavalli SN; Pal-Bhadra M; Srivastava HK; Narahari Sastry G; Juvekar A; Sen S; Zingde S
    Bioorg Med Chem; 2010 Jan; 18(2):526-42. PubMed ID: 20031423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.